15. Use of lidocaine in the manufacture of a medicament for the treatment of bladder pain and/or irritative voiding symptoms, wherein the medicament is to be continuously administered to the bladder of the patient in an amount effective to achieve a ~~measurable plasma concentration of the lidocaine in the patient continuously over a treatment period of at least 24 hours~~therapeutic effect which is sustained beyond an end of the treatment period,

~~and~~ wherein the lidocaine is ~~released~~ to be administered continuously ~~into the bladder of the patient for~~over a treatment period of from 2 to 28 days,

wherein a cumulative amount of the lidocaine (FBE) administered over the treatment period is between 150 mg and 1000 mg.

16. The use of claim 15, wherein the lidocaine is to be administered~~released~~ continuously into the bladder for between 2 and 14 days.

~~17. The use of claim 15, wherein the continuous administration is into a patient's bladder from a device delivering between 150 and 1000 mg of lidocaine (FBE).~~